Hook / Thesis
Waystar is a healthcare payments software specialist that looks inexpensive relative to its growth profile and margin profile when you strip out market volatility. The business is driven by recurring subscription revenue, improving adjusted EBITDA margins and a strategic push into AI-powered billing automation. Those factors, combined with a clean balance sheet and strong free cash flow, justify a mid-term buy at current prices.
We are initiating a trade idea to buy Waystar at $23.95 with a clear stop at $20.50 and a target of $32.00. The thesis: steady subscription growth and accelerating AI adoption should lift revenue and leverage margins over the next several quarters, producing outsized upside versus the current market capitalization of roughly $4.6B.
What Waystar Does and Why It Matters
Waystar builds enterprise-grade cloud software that simplifies healthcare payments for providers, patients and payers. The core value proposition is operational efficiency and cash collection improvement: hospitals and health systems can reduce claim denials, speed payment cycles and lower administrative headcount with Waystar's platform. In an industry where margins are tight and revenue cycles are complex, a platform that materially improves collections is mission-critical.
Why the market should care: healthcare payment complexity is not going away, but it is ripe for automation. The industry is adopting AI to sort claims, predict denials and automate patient billing interactions. Waystar's roadmap and recent wins position it to capture a larger slice of the growing AI-in-medical-billing market, which research projects will expand meaningfully over the next 5-7 years.
Hard Numbers That Support the Thesis
| Metric | Value |
|---|---|
| Market cap | $4.59B |
| Last reported revenue (FY / quarter highlights) | $1.10B (revenue up 17% YoY); Q2 revenue $270.7M, +15% YoY |
| Adjusted EBITDA | $462M (up 21% YoY), adjusted EBITDA margin ~42% |
| Free cash flow | $246.26M |
| P/E | ~33.94 (based on EPS ~$0.70) |
| EV / EBITDA | ~13.94 |
| 52-week range | $17.26 - $40.98 |
Two points stand out: recurring revenue scale and cash conversion. Recent commentary and results show revenue north of $1.1B and strong adjusted EBITDA growth (adjusted EBITDA of $462M). Free cash flow generation of about $246M gives the company flexibility to invest in AI, tuck-in M&A or buy back stock if management chooses. At a market cap near $4.6B and enterprise value roughly $6.03B, valuation multiples (EV/EBITDA ~14, price-to-sales ~3.8) are reasonable for a growth SaaS business that is already profitable and cash-generative.
Valuation Framing
Waystar trades at a P/E around 34 and EV/EBITDA near 14. Those multiples are modest for a profitable, cash-generating software firm with mid-teens revenue growth and high adjusted margins. The stock pulled back from a 52-week high of $40.98 to a low of $17.26 earlier in the year; today it trades around $23.95, close to its 50-day moving average ($23.75) but below the 20-day (~$24.98) and 10-day (~$25.23). That positioning suggests the market is cautious but not panicked, creating an entry zone where upside from executed AI initiatives and subscription acceleration can outpace multiple expansion.
Catalysts to Drive the Trade
- Quarterly reacceleration: continued revenue beats and guidance raises, building on Q2 results where revenue rose 15% YoY and management raised full-year guidance.
- AI product rollouts and client wins: adoption of AI-powered billing automation and analytics that increase AR collections and reduce days in accounts receivable.
- Tuck-in M&A: opportunistic acquisitions (management has signaled intent with prior deals) to expand addressable market or add margin-accretive functionality.
- Macro stability in hospital reimbursement and higher patient-pay adoption pushing more providers to SaaS payment platforms.
Trade Plan (Actionable)
- Trade direction: Long.
- Entry price: $23.95 (current price).
- Stop loss: $20.50 (protects capital if support near the mid-$20s fails).
- Target price: $32.00 (the trade implies ~34% upside from entry; consistent with re-rating toward prior multiple and continued revenue/margin improvement).
- Horizon: mid term (45 trading days). This horizon balances the cadence of quarterly results and product announcements; it allows time for a combination of operational beats and market re-rating while limiting exposure to longer-term macro shifts.
Position sizing should reflect the stop distance and a trader's risk tolerance. With a stop at $20.50, the downside from entry is about $3.45 per share; cap risk to a small percentage of portfolio value consistent with your overall allocation rules.
Technical and Sentiment Context
Technicals are mixed: RSI sits near 46, MACD shows bearish momentum in the near term, and the stock trades slightly below the 10- and 20-day EMAs. Short interest and short-volume activity have been meaningful: days-to-cover figures hover around 4-5 days and recent short volume has been elevated on some sessions. That adds a sentiment component: if earnings or product news surprises positively, short covering could amplify upside.
Risks and Counterarguments
- Execution risk on AI and product rollouts: AI features must demonstrate clear ROI for providers. If deployments are slower or customers fail to extract the promised collection gains, adoption could lag and revenue acceleration may disappoint.
- Reimbursement and policy risk: changes in payer rules, coding, or reimbursement could depress provider economics and reduce willingness to spend on third-party platforms.
- Valuation compression if growth slows: despite solid margins, the stock could re-rate lower if revenue growth dips below expectations; P/E ~34 leaves less room for error than for a loss-making high-growth SaaS.
- Sentiment and liquidity swings: the name has experienced heavy short-volume days; a prolonged negative macro environment or risk-off in software could exacerbate outflows and push shares below the stop.
- Counterargument - The bears have a point: the stock is not cheap on an absolute multiple basis and healthcare IT can be lumpy. If macro headwinds or capital constraints cause providers to delay projects, Waystar's 15-17% revenue growth profile could cool and the multiple could contract further.
What Would Change My Mind
I would reconsider this buy if any of the following occurs: management lowers full-year guidance or we see a material slowdown in subscription bookings; adjusted EBITDA margins roll over materially; or free cash flow turns negative. Conversely, I would upgrade the target and increase conviction if Waystar posts two consecutive quarters of revenue beats with clear signs of AI-driven AR improvement and larger-than-expected gross retention gains.
Conclusion
Waystar sits at an attractive intersection of recurring revenue, strong adjusted profitability and a clear runway to monetize AI in medical billing. The stock's pullback has created a pragmatic entry point for a mid-term trade: buy at $23.95, protect at $20.50, and target $32.00 over roughly 45 trading days. The plan balances upside from operational execution and multiple expansion against identifiable execution and policy risks. Monitor quarterly results, AI adoption metrics and any guidance changes closely - those items will determine whether the thesis plays out or requires reassessment.
Key catalysts to watch: quarterly revenue/EBITDA beats, AI deployment announcements, and any accretive M&A that expands product depth.